

BPV Case ID _____

Affix BPV Case ID Barcode Label

Tissue Bank ID: _____

Form Completed By: _____

Date Form Was Completed: __/__/_____
 (MM/DD/YYYY)

Kidney Slide Pathology Review

1. Slide ID examined by pathologist:

2. Parent specimen ID of the sample from which this slide was derived:

3. Organ of origin:

Select One:

- Kidney
- Other (specify)

Specify other organ of origin:

If Other was selected, specify other organ of origin:

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: ___/___/_____
 MM/DD/YYYY

4. Histologic type:

Select One:

- Carcinoma associated with neuroblastoma
- Carcinoma of the collecting ducts of Bellini (WHO code: 8319/3)
- Chromophobe renal cell carcinoma (WHO code: 8317/3)
- Clear cell renal carcinoma (WHO code: 8310/3)
- Mucinous tubular and spindle cell carcinoma
- Multilocular clear cell renal carcinoma (WHO code: 8310/3)
- Papillary renal cell carcinoma (WHO code: 8260/3)
- Renal cell carcinoma, unclassified (WHO code: 8312/3)

- Renal medullary carcinoma (WHO code: 8319/3)
- Translocation carcinoma (Xp11 or others)
- Tubulocystic renal cell carcinoma
- Other (specify)

Specify other histologic type:

If Other was selected, record other histologic type:

5. Presence of sarcomatoid features:

Select one:

- Not identified
- Present

Describe sarcomatoid features:

If present, describe sarcomatoid features:

BPV Case ID: _____	Tissue Bank ID: _____
Form Completed By: _____	Date Completed: ____/____/_____ MM/DD/YYYY

6. Greatest tumor dimension on slide:	_____ (mm)	
7. Percent of cross-sectional surface area of entire slide composed of tumor focus (includes necrotic tumor):	_____ %	
8. Percent of tumor nuclei by cell count of the entire slide (number of tumor epithelial cell nuclei as compared to all cell nuclei):	_____ %	
9. Percent of cross-sectional surface area of entire slide composed of necrotic tissue:	_____ %	

Note: BPV case acceptance criteria require necrosis percentage of <20% of the entire slide AND tumor content of ≥50% tumor nuclei.

PR-0009-F1

VER. 03.02

Effective Date: 07/16/2014

Page 4 of 7

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

Histologic Profile Quantitative Assessment of Tumor Should Total 100%.

10. Histologic profile quantitative assessment:	Percent viable tumor by surface area (not including stroma)	%	
	Percent necrotic tumor by surface area:		
	Percent tumor stroma by surface area:		
	Percent non-cellular component by surface area (i.e., mucin, hemorrhage, blood clot, etc.): If present, describe non-cellular component:		
	Histologic profile total % (should equal 100%):		
11. Histologic grade (Fuhrman nuclear grading system):	Select one: <input type="radio"/> G1: Nuclei round, uniform, approximately 10µm; nucleoli inconspicuous or absent <input type="radio"/> G2: Nuclei slightly irregular, approximately 15µm; nucleoli evident <input type="radio"/> G3: Nuclei very irregular, approximately 20µm; nucleoli large and prominent <input type="radio"/> G4: Nuclei bizarre and multilobulated, 20µm or greater; nucleoli prominent, chromatin clumped <input type="radio"/> GX: Cannot be assessed		

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: ___/___/_____
 MM/DD/YYYY

Tumor Staging per AJCC 7th Edition

12. pT: Pathologic spread primary tumor (AJCC 7th edition):

Select one:

- pTX
- pT0
- pT1
 - pT1a
 - pT1b
- pT2
 - pT2a
 - pT2b
- pT3
 - pT3a
 - pT3b
 - pT3c
- pT4

13. pN: Pathologic spread lymph nodes (AJCC 7th edition):

Select one:

- pNX
- pN0
- pN1

14. M: Distant metastases (AJCC 7th edition):

Select one:

- cM0
- cM1
- pM1

15. Pathologic tumor stage group (AJCC 7th edition):

Select one:

- Stage I
- Stage II
- Stage III
- Stage IV

PR-0009-F1

VER. 03.02

Effective Date: 07/16/2014

Page 6 of 7

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

16. Did pathology review of the hematoxylin and eosin slide derived from quality control formalin-fixed paraffin-embedded tumor tissue confirm the histological type to be eligible for BPV study?

Select one:
 Yes
 No

17. This slide meets the microscopic analysis criteria of the BPV project of necrosis percentage of <20% AND tumor content of ≥50% tumor nuclei:

Select one:
 Yes
 No
If No is selected, specify what findings do not meet the microscopic analysis criteria of the BPV project:

18. Pathology review comments:

BPV Case ID: _____

Tissue Bank ID: _____

Form Completed By: _____

Date Completed: __/__/____
 MM/DD/YYYY

Concordance With Diagnostic Pathology Report

19. This slide is consistent with the findings of the diagnostic pathology report for this case:

Select One:

Yes

No

If No is selected, specify what findings are not consistent with the diagnostic pathology report:

20. Name of local biospecimen source site reviewing pathologist:

21. Date of slide review by the pathologist:

22. Data entry in local pathology review form was performed by: